KR20190046935A - 엔자스타우린의 활성을 예측하기 위한 방법 및 조성물 - Google Patents

엔자스타우린의 활성을 예측하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20190046935A
KR20190046935A KR1020197009407A KR20197009407A KR20190046935A KR 20190046935 A KR20190046935 A KR 20190046935A KR 1020197009407 A KR1020197009407 A KR 1020197009407A KR 20197009407 A KR20197009407 A KR 20197009407A KR 20190046935 A KR20190046935 A KR 20190046935A
Authority
KR
South Korea
Prior art keywords
snps
treatment
sequence
group
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197009407A
Other languages
English (en)
Korean (ko)
Inventor
웬 루오
홍 선
Original Assignee
드노보 바이오파마 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 드노보 바이오파마 엘엘씨 filed Critical 드노보 바이오파마 엘엘씨
Publication of KR20190046935A publication Critical patent/KR20190046935A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197009407A 2016-09-01 2017-08-31 엔자스타우린의 활성을 예측하기 위한 방법 및 조성물 Ceased KR20190046935A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662382734P 2016-09-01 2016-09-01
US62/382,734 2016-09-01
US201662414601P 2016-10-28 2016-10-28
US62/414,601 2016-10-28
PCT/US2017/049747 WO2018045240A1 (en) 2016-09-01 2017-08-31 Methods and composition for the prediction of the activity of enzastaurin

Publications (1)

Publication Number Publication Date
KR20190046935A true KR20190046935A (ko) 2019-05-07

Family

ID=59923555

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197009407A Ceased KR20190046935A (ko) 2016-09-01 2017-08-31 엔자스타우린의 활성을 예측하기 위한 방법 및 조성물

Country Status (15)

Country Link
US (2) US11421280B2 (https=)
EP (1) EP3507384B1 (https=)
JP (3) JP7197915B2 (https=)
KR (1) KR20190046935A (https=)
CN (1) CN109952383B (https=)
AU (1) AU2017318669B2 (https=)
BR (1) BR112019003951A2 (https=)
CA (1) CA3035386A1 (https=)
JO (1) JOP20190025A1 (https=)
MX (1) MX2019002377A (https=)
PH (1) PH12019500422A1 (https=)
RU (1) RU2019109011A (https=)
SG (2) SG11201901762WA (https=)
TW (2) TWI771317B (https=)
WO (1) WO2018045240A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
CN110496223B (zh) * 2018-05-17 2021-09-10 复旦大学附属肿瘤医院 一种治疗非霍奇金氏淋巴瘤的药物组合物
CN112512527A (zh) * 2018-09-12 2021-03-16 杭州索元生物医药股份有限公司 恩扎妥林和btk抑制剂的组合及其用途
CN111549033B (zh) * 2020-06-11 2021-02-12 南京市江宁医院 慢病毒感染人表皮角质细胞株及其构建方法和应用
US11227690B1 (en) * 2020-09-14 2022-01-18 Opendna Ltd. Machine learning prediction of therapy response
WO2023001178A1 (zh) * 2021-07-23 2023-01-26 高雄医学大学 用于评估二代荷尔蒙药物治疗前列腺癌疗效的临床治疗药物预测和推荐系统及方法
US20230131677A1 (en) * 2021-10-21 2023-04-27 Toyota Research Institute, Inc. Systems and methods for predicting the effect of an intervention via machine learning
CN118339312A (zh) * 2021-11-23 2024-07-12 索元生物医药(美国)有限公司 用于评估多核苷酸递送和癌疗法之功效的组合物和方法
US12474842B2 (en) * 2021-12-13 2025-11-18 Google Llc Optimizing data placement based on data temperature and lifetime prediction

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
AU2001285047A1 (en) * 2000-08-16 2002-02-25 Chiron Corporation Human genes and gene expression products
US20040072217A1 (en) 2002-06-17 2004-04-15 Affymetrix, Inc. Methods of analysis of linkage disequilibrium
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
WO2007145992A2 (en) 2006-06-05 2007-12-21 Perlegen Sciences, Inc. Genetic basis of treatment response in depression patients
AU2012212499A1 (en) 2011-01-31 2013-08-22 Denovo Biomarkers Inc. Method for discovering pharmacogenomic biomarkers
KR20140039278A (ko) 2011-06-08 2014-04-01 드노보 바이오파마 (항주) 리미티드 코포레이션 레티노이드 x 수용체 모듈레이터 활성 예측 방법 및 조성물
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين

Also Published As

Publication number Publication date
SG11201901762WA (en) 2019-03-28
AU2017318669A1 (en) 2019-03-07
WO2018045240A1 (en) 2018-03-08
US11421280B2 (en) 2022-08-23
JP2020188816A (ja) 2020-11-26
CA3035386A1 (en) 2018-03-08
MX2019002377A (es) 2019-09-05
JP2022173308A (ja) 2022-11-18
TW202313973A (zh) 2023-04-01
PH12019500422A1 (en) 2019-05-27
AU2017318669B2 (en) 2023-04-20
JOP20190025A1 (ar) 2019-02-19
TW201812125A (zh) 2018-04-01
EP3507384A1 (en) 2019-07-10
BR112019003951A2 (pt) 2019-06-25
CN109952383B (zh) 2024-01-05
JP7197915B2 (ja) 2022-12-28
SG10201912134TA (en) 2020-02-27
US20230074781A1 (en) 2023-03-09
US20190233902A1 (en) 2019-08-01
EP3507384B1 (en) 2023-08-30
JP2019528705A (ja) 2019-10-17
RU2019109011A (ru) 2020-10-05
TWI771317B (zh) 2022-07-21
RU2019109011A3 (https=) 2021-01-22
CN109952383A (zh) 2019-06-28

Similar Documents

Publication Publication Date Title
US20230074781A1 (en) Methods and composition for the prediction of the activity of enzastaurin
CN102177436B (zh) 鉴定疾病风险因子的方法
US20210108266A1 (en) Method for discovering pharmacogenomic biomarkers
CN113646443A (zh) 用于诊断神经胶质瘤或预测预后的组合物以及提供其相关信息的方法
US10954563B2 (en) Method for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment
US20240417801A1 (en) Compositions and methods for assessing the efficacy of polynucleotide delivery and cancer therapy
TW202146660A (zh) 用於評估神經傳導物轉運子抑制劑之功效之組合物及方法
US12612661B2 (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters
HK40011257B (en) Methods and composition for the prediction of the activity of enzastaurin
HK40011257A (en) Methods and composition for the prediction of the activity of enzastaurin
HK40083504A (en) Compositions and methods for assessing the efficacy of inhibitors of neurotransmitter transporters

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190401

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200825

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230719

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240131

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240403

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240131

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20230719

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I